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Purpose: This study was undertaken to evaluate our results of  polytetrafluoroethylene 
(PTFE) tibial and peroneal artery bypasses done for limb salvage. 
Methods: Within a group of patients undergoing infrainguinal limb salvage bypasses at our 
institution between January 1986 and May 1995, 63 patients faced an immediate 
amputation, had no autologous vein on duplex examination and operative xploration, and 
had only a tibial or peroneal artery as an outflow vessel for bypass. Most of  these patients 
(82%) had two or more prior ipsilateral infrainguinal bypasses. These 63 patients 
underwent 66 PTFE bypasses to a tibial or peroneal artery without a distal anastomotic 
vein cuffor an adjunctive arteriovenous fi tula. Our results were then compared with those 
reported from infrapopliteal (crural) bypasses performed with alternate autologous vein 
sources or PTFE in conjunction with various recommended adjuncts. 
Results: The 3- and 5-year cumulative primary graft patency rates for our PTFE 
infrapopliteal bypasses were 39% + 7% and 28% + 9%, respectively. Secondary graft 
patency rates were 55% +- 8% and 43% + 10% at 3 and 5 years, respectively. Limb salvage 
rates were 71% + 7% at 3 years and 66% +- 8% at 5 years. Two-year actuarial patient 
survival rate was only 67% + 7%. 
Conclusions: These results indicate that a PTFE bypass to an infrapopliteal rtery remains 
a worthwhile option in patients without usable autologous vein. The secondary patency 
and limb salvage rates were acceptable in this setting and were not significantly different 
from the best results reported with prosthetic tibial/peroneal bypasses with distal vein cuffs 
or patches (74% at 1 year; 58% at 3 years), arteriovenous fistulas (71% at 1 year) or 
composite arm vein grafts (39% and 29% at 3 and 5 years, respectively). (J VASC SURG 
1996;23:347-56.) 
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Autogenous greater saphenous vein is the graft 
material of choice for infrainguinal bypass both in 
terms of  primary patency and limb salvage} Two 
attributes of autogenous vein distinguish it from all 
available substitutes: a living endothelial cell-lined 
flow surface and mechanical properties more akin to 
those of native arteries. 2 Despite the theoretic and 
observed advantages of autologous vein over other 
conduits, vein grafts have a significant occlusion rate 
(25% to 40% at 5 years) when they are used for lower 
extremity revascularization. 14 After such vein graft 
failures, patients may remain symptom free; how- 
ever, recurrence of rest pain or tissue loss mandates 
further evascularization to avoid amputation. Un- 
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foramately, many patients requiring secondary evas- 
cularizations do not have autologous vein of suffi- 
cient length or quality to provide the required con- 
duit. In addition, unsuspected preexisting disease 
may be present in 12% of normal-appearing veins) If 
the patient has a patent popliteal artery, polytetraflu- 
oroethylene (PTFE) can be used and is certainly a
better option than is a poor vein or one with preexist- 
ing disease. 5 Graft patency and limb salvage rates are 
acceptable, ven if the outflow popliteal artery seg- 
ment has relatively poor outflow. 6However, those 
patients without a patent popliteal artery will require 
a tibial or peroneal (crural) bypass to achieve limb 
salvage. It is in this latter group of patients that sig- 
nificant controversy exists regarding the merits or 
value of an iufrapopliteal bypass with PTFE. 
In 1978 we first reported on the use of PTFE 
grafts to tibial and peroneal arteries for limb salvage 
with acceptable early results.7 However, several other 
reports, including our own, indicated that longer 
term results were less encouraging. 8'9We reported a 
4-year primary patency rate of only 12% in our 
randomized, prospective study, although the limb 
salvage results were far superior (61% at 4 years)) 
Because of these suboptimal results with iufrapopli- 
teal PTFE bypasses, some investigators have sug- 
gested that major amputation is a better option than 
an attempt at revascularization. 1° Others have sug- 
gested that anticoagulation with warfarin (Couma- 
din) or the use of vein cuffs, patches, or arteriovenous 
fistulas (AVFs) at the distal anastomosis will improve 
patency results, although the value of these adjuncts 
remains unproven. 11-17 
However, we and others have continued to 
perform infrapopliteai PTFE bypasses with Couma- 
din anticoagulation but without any of these surgical 
adjuncts in patients who have no suitable autologous 
vein and were otherwise facing a major ampu- 
tation. 1821 This long-term retrospective study was 
undertaken to evaluate whether these unmodified 
PTFE tibia] and peroneal bypasses were worthwhile 
and how these results compare with those of infra- 
popliteal bypasses performed with the various rec- 
ommended surgical adjuncts. 
MATERIAL AND METHODS 
Between January 1986 and May 1995, a total of 
1077 lower extremity bypasses were performed for 
limb salvage at ottr institution. Of these, 66 PTFE 
bypasses to infrapopliteal rteries were performed 
without adjunctive cuffs, patches, or AVFs in 63 
patients (33 men; 30 women). These 66 bypasses 
form the basis for this retrospective r view. All were 
performed inpatients who without revascularization 
would have required an urgent amputation because 
of progressive necrosis, infection, or intolerable 
ischemic rest pain. 
The patients in this study were identified by a 
search of our computer database. Hospital, operating 
room, and office records were also reviewed. Age, 
sex, and the presence of diabetes, coronary artery 
disease, and hypertension were recorded. Risk factors 
in the study patients included diabetes mellitus 
(67%), medically controlled hypertension (47%), 
and coronary artery disease (53%). Thirty-two per- 
cent had undergone previous coronary artery bypass. 
All patients were proven by duplex ultrasonography 
and operative xploration to have no usable autolo- 
gous vein. Usable autologous vein was defined as a 
vein that has a diameter greater than 3 mm after 
dilation and one that permits passage of a catheter 
through the entire lumen. This would include lesser 
saphenous and arm veins. We rarely perform more 
than three venovenous anastomoses. Fifty-four pa- 
tients (82%) had undergone at least two or more 
prior infrainguinal arterial bypasses. Most primary 
bypasses were performed with ipsilateral greater 
saphenous vein, and the secondary bypasses were 
performed with a combination of contralateral 
greater saphenous vein, alternate vein, PTFE to the 
popliteal artery, and composite PTFE-vein, in that 
order of preference. 
All patients underwent preoperative noninvasive 
testing, which included pulse volume recordings and 
Doppler scanning-determined s gmental pressures. 
Arteriography from the renal arteries to the forefoot 
was performed before operation in all patients. 19,22 
Primary and secondary patency rates, limb salvage 
rates, and patient survival rates were tabulated by the 
cumulative life-table method. 23 Primary patency was 
defined as continuous graft patency, uninterrupted 
by an interventional procedure on the graft. Second- 
ary patency was defined as patency up to the time of 
final graft closure and includes the results of reinter- 
vention for thrombosed or failing grafts. Limb 
salvage was defined as the preservation of a viable 
limb with a functional portion of the foot. 
RESULTS 
Four patients died during the 30-day postopera- 
tive period, resulting in a perioperative mortality rate 
of 6%. Follow-up ranged from i to 86 months (mean 
52 months). Follow-up examination was performed 
at 1 and 6 weeks after revascularization, every 3 
months for the next 2 years, and then at 6-month 
intervals thereafter. If there was any change in 
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Table I. Primary patency of PTFE bypasses to an infrapopliteal artery 
s~of 
Interval Interval Cumulative cumulative SE of 
No. of No. of No. of failure patency patency patency Hazard hazard 
Interval grafts grafts grafts rate rate rate rate rate rate 
(mos.) at r isk withdrawn failing (%) (%) (%) (%) (%) (%) 
0-1 66 5 6 9 91 91 4 10 4 
1-3 55 2 3 6 94 86 5 3 2 
3-6 50 1 3 6 94 80 5 2 1 
6-9 46 0 3 7 93 75 6 2 1 
9-12 43 5 2 5 95 71 6 2 1 
12-15 36 5 5 15 85 61 7 5 2 
15-18 26 0 1 4 96 58 7 1 1 
18-21 25 0 4 16 84 49 7 6 3 
21-24 21 1 1 5 95 47 7 2 2 
24-27 19 1 3 16 83 39 7 6 3 
27-30 15 2 0 0 100 39 7 0 0 
30-33 13 1 0 0 100 39 7 0 0 
33-36 12 0 0 0 100 39 7 0 0 
36-39 12 2 1 9 91 36 7 3 3 
39-42 9 0 0 0 100 36 7 0 0 
42-45 9 0 0 0 100 36 7 0 0 
45-48 9 0 0 0 100 36 7 0 0 
48-51 9 1 0 0 100 36 7 0 0 
51-54 8 3 0 0 100 36 7 0 0 
54-57 5 0 1 20 80 28 9 7 7 
57-60 4 0 0 0 100 28 9 0 0 
Table II. Secondary patency rate of PTFE bypasses to an infrapopliteal artery 
~of  
Interval Interval Cumulative cumulative SE of 
No. of No. of No. of failure patency patency patency Hazard hazard 
Interval grafts grafts grafts rate rate rate rate rate rate 
(mos.) at r isk withdrawn failing (%) (%) (%) (%) (%) (%) 
0-1 66 5 3 5 95 95 3 5 3 
1-3 58 3 3 5 95 90 4 3 2 
3-6 52 1 3 6 94 85 5 2 1 
6-9 48 0 3 6 94 80 5 2 1 
9-12 45 6 1 2 98 78 6 1 1 
12-15 38 6 3 9 91 71 6 3 2 
15-18 29 1 1 4 96 69 7 1 1 
18-21 27 0 2 7 93 64 7 3 2 
21-24 25 2 1 4 96 61 7 1 1 
24-27 22 2 2 10 90 55 8 3 2 
27-30 18 2 0 0 100 55 8 0 0 
30-33 16 1 0 0 100 55 8 0 0 
33-36 15 0 0 0 100 55 8 0 0 
36-39 15 2 1 7 93 51 8 3 3 
39-42 12 1 0 0 100 51 8 0 0 
42-45 11 0 0 0 100 51 8 0 0 
45-48 11 0 0 0 100 51 8 0 0 
48-51 11 1 0 0 100 51 8 0 0 
51-54 10 4 0 0 100 51 8 0 0 
54-57 6 0 0 0 100 51 8 0 0 
57-60 6 0 1 2 83 43 10 6 6 
physical  f indings or  symptoms,  a duplex  examinat ion  
was per fo rmed.  I f  any abnormal i t ies  were  noted ,  the 
pat ient  underwent  arter iography.  Thrombectomy or  
th rombo lys i s  w i th  urok inase was used  for  PTFE  graft  
th rombos is .  A pers istent ,  focal ang iograph ic  defect  
was t reated w i th  percutaneous  ba l loon  angioplasty  or  
appropr ia te  surgical revis ion (patch angioplasty  or  
extens ion) .  For  di f fuse or  occlusive in f low lesions or  
p rogress ion  o f  distal disease, surgical in tervent ion  
was requ i red  w i th  a prox imal  or  distal extens ion  or  a 
JOURNAL OF VASCULAR SURGERY 
350  Parsons et aL February 1996 
Table III. Limb salvage after PTFE bypass to an infrapopliteal rtery 
S~of 
Interval Interval Cumulative cumulative SE of 
No. of No. of No. of failure patency patency patency Hazard hazard 
Interval grafts grafts grafts rate rate rate rate rate rate 
(mos.) at r isk withdrawn failing (%) (%) (%) (%) (%) (%) 
0-1 66 5 3 5 95 95 3 5 3 
1-3 57 3 3 5 95 90 4 3 2 
3-6 51 2 1 2 98 88 4 1 1 
6-9 48 2 0 0 100 88 4 0 0 
9-12 46 5 2 5 95 84 5 1 1 
12-15 39 7 2 6 94 80 6 2 1 
15-18 30 2 0 0 100 80 6 0 0 
18-21 28 1 3 11 89 71 7 3 2 
21-24 24 3 0 0 100 71 7 0 0 
24-27 21 3 0 0 100 71 7 0 0 
27-30 18 1 0 0 100 71 7 0 0 
30-33 17 2 0 0 100 71 7 0 0 
33-36 15 0 0 0 100 71 7 0 0 
36-39 15 1 0 0 100 71 7 0 0 
39-42 14 1 1 7 93 66 8 2 3 
42-45 12 0 0 0 100 66 8 0 0 
45-48 12 0 0 0 100 66 8 0 0 
48-51 12 1 0 0 100 66 8 0 0 
51-54 11 4 0 0 100 66 8 0 0 
54-57 7 0 0 0 100 66 8 0 0 
57-60 7 1 0 0 100 66 8 0 0 
Table IV. Survival after PTFE bypass to an infrapopliteal rtery 
Interval Interval 
No. of No. of mortality survival 
Interval patients patients "No. of rate rate 
(mos.) at r isk withdrawn deaths (%) (%) 
S~of 
Cumulative cumulative SE of 
survival survival Hazard hazard 
rate rate rate rate 
(%) (%) (%) (%) 
0-1 63 5 4 7 93 " 
1-3 54 5 1 2 98 
3-6 48 1 i 2 98 
6-9 46 2 1 2 98 
9-12 43 5 3 7 93 
12-15 35 4 3 9 91 
15-18 28 2 0 0 100 
18-21 26 3 1 4 96 
21-24 22 2 1 5 95 
24-27 19 3 1 6 94 
27-30 15 1 0 0 100 
30-33 14 1 1 7 93 
33-36 12 0 0 0 100 
36-39 12 1 1 9 91 
39-42 10 1 0 0 100 
42-45 9 0 0 0 100 
45-48 9 0 0 0 100 
48-51 9 1 0 0 100 
51-54 8 1 1 1 87 
54-57 6 0 0 0 100 
57-60 6 0 1 2 83 
93 3 7 3 
92 4 1 1 
90 4 1 1 
88 4 1 1 
81 5 3 2 
74 6 3 2 
74 6 0 0 
71 7 1 1 
67 7 2 2 
64 8 2 2 
64 8 0 0 
59 9 3 3 
59 9 0 0 
54 9 3 3 
54 9 0 0 
54 9 0 0 
54 9 0 0 
54 9 0 0 
47 10 5 5 
47 10 0 0 
39 11 6 6 
new bypass graft by use of previously described 
principles and techniques for the management of
failed or falling lower extremity bypasses.  20'24 Six 
grafts (9%) failed in the first 30 days. Nine throm- 
bectomies were performed in six patients; urokinasc 
was used eight times in six patients; one patient had 
thrombolysis with angioplasty; two patients had 
femorofemoral bypasses; and two patients had distal 
extensions performed after thrombectomy or throm- 
bolysis. One patient had a vein patch angioplasty and 
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was excluded from further study. Two other patients 
whose grafts were considered complete failures 
underwent repeat PTFE tibial bypasses, and the 
grafts were reentered in the study as new PTFE tibial 
bypasses. Five patients with bleeding or hematoma 
underwent reexploration. 
The 3- and 5-year cumulative primary graft 
patency rates for the infrapopliteal bypasses were 
39% -+ 7% and 28% +- 9%, respectively (Table I). 
The secondary graft patency rates were 55% - 8% 
and 43% _+ 10% at 3 and5 years, respectively (Table 
II). The limb salvage rates were 71% -+ 7% at 3 years 
and 66% _+ 8% at 5 years (Table III). The five-year 
actuarial survival rate in this group of patients was 
only 38% (Table W). 
DISCUSSION 
Infrainguinal arterial reconstruction i the ab- 
sence of suitable autologous tissue presents a chal- 
lenge for the vascular surgeon and the patient. Many 
surgeons believe that major amputation is preferable 
to an infrapopliteal rtery bypass with a PTFE graft 
when a limb is threatened and no autologous vein is 
available. 8~° However, as part of our aggressive 
approach to limb salvage, we have believed that the 
use of PTFE grafts in these circumstances is indicated 
for patients who would otherwise require immediate 
amputation. 1,19,2°,22 The primary and secondary pa- 
tency rates for PTFE bypasses in this study are clearly 
inferior to those for greater saphenous vein. How- 
ever, 78% of the PTFE grafts in our study remained 
patent for 1 year and 55% for 3 years. Although the 
proportion of patients urviving 5 years after their 
PTFE bypass was small, the cumulative secondary 
patency rate at 5 years was 43%. These patency rates 
are similar to those reported by Flinn et al.,n 
Schweiger et al.,18 and Fichelle et al.2s (Table V). 
Despite these relatively poor patency rates, long- 
term limb salvage in our series has been surprisingly 
good. The limb salvage rates in our patients were 
71% and 66% at 3 and 5 years, respectively. There are 
several possible reasons why the limb salvage rates 
were better than the patency rates. First, at the time 
of graft failure many of our patients had healed 
infected, ulcerated, or gangrenous lesions, and these 
lesions did not recur after the graft failed. Second, 
even if these lesions had not completely healed, many 
of them improved sufficiently and could be conser- 
vatively managed without the need for amputation. 
Third, our aggressive policy of graft revision, exten- 
sion, or replacement with a new PTFE graft permit- 
ted longer limb salvage after primary graft failure. 2° 
The addition of coumarin derivatives to the 
treatment of patients requiring infrapopliteal by- 
passes with PTFE is often cited as an important factor 
in improving the patency of these bypasses. The 
overall patency rate in the series reported by Flinn et 
al.~ was lower than that in our series. However, in 
their subgroup with adequate anticoagulation (PT > 
18), the primary patency rates at 2 and 4 years were 
59% and 50%, respectively, which are somewhat 
better than our primary patency rates. However, 
most of the patients in the series (n = 149) reported 
by Schweiger et al}8 received aspirin alone with 
comparable r sults. Unless contraindicated, we rou- 
tinely used Coumadin or warfarin in our patients 
undergoing infrapopliteal reconstructions. The inter- 
national normalized ratio was not used at our 
institution during a major portion of the study 
period. The prothrombin time was kept at 11/2 to 21/2 
times control. We currently use an international 
normalized ratio of 21/2 to 3. However, the benefits 
of anticoagulation i these patients remains to be 
clearly demonstrated and would require a large, 
randomized, prospective trial. 
The most common alternative conduits in the 
absence of greater saphenous vein are lesser saphe- 
nous vein, arm vein, and, if these prove inadequate, 
PTFE grafts, possibly with the addition of vein cuffs, 
patches, or AVFs at the distal anastomosis. The 
concept of using AVFs to save ischemic limbs was 
first conceived of in 1902. 26 Most recently, the use of 
AVFs has been proposed as an adjunct o prosthetic 
bypasses in the belief that creation of an AVF 
decreases the vascular esistance of the distal arterial 
bed, which, in turn, increases the flow through the 
prosthetic graft, thereby improving patency. Dardik 
et al}2 reported a 2-year patency rate of 44% in 69 
patients with the routine use of AVFs in prosthetic or 
umbilical vein bypasses to the infrapopliteal rteries. 
Paty et al)s achieved a 1-year patency rate of 67% and 
a limb salvage rate of 75 % when remote, distal AVFs 
were used with PTFE crural bypasses, and Jacobs et 
al}6 showed similar short-term results. All these 
results are not significantly better than those for 
PTFE infrapopliteal bypasses without the use of 
AVFs in our study. 
The use of vein cuffs or patches at the distal 
anastomosis has attracted increasing interest in recent 
years. 143~,2s,27,28 The rationale for the addition of a 
vein cuff or patch to the distal anastomosis to 
prevent anastomotic narrowing caused by intimal 
hyperplasia by widening the anastomosis with au- 
tologous tissue. In addition, vein cuff interposition 
between PTFE and native artery has been shown to 
inhibit jux~aanastomotic neointimal hyperplasia nan 
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Table V. Recent patency and limb salvage rates with PTFE infrapopliteal bypasses 
1 Year 2 Years 3 Years 4 Years 5 Years 
Author No. of patients (%) (%) (%) (%) (%) 
Current series, 1995 66 
Primary patency rate 71 47 39 36 28 
Secondary patency rate 78 61 55 51 43 
Limb salvage rate 84 71 71 66 66 
Veith et al., 1986 ~ 98 
Primary patency rate 48 35 33 12 - 
Secondary patency rate . . . . .  
Limb salvage rate 76 64 61 61 - 
Flinn et al., 1988 n 75 
Primary patency rate - 45 - 37 - 
Secondary patency rate . . . . .  
Limb salvage rate . . . . .  
Whittemore t al., 198933 21 
Primary patency rate 25 12 12 12 12 
Secondary patency rate . . . . .  
Limb salvage rate . . . . .  
Quifiones-Baldrich et al., 28 
199221 
Primary patency rate 44 40 22 22 22 
Secondary patency rate . . . . .  
Limb salvage rate - - 37 - - 
Schweiger t al., 199318 211 
Primary patency rate 51 46 37 31 27 
Secondary patency rate 63 60 45 38 34 
Limb salvage rate - 63 - - 51 
Fichelle t al., 19952s 31 
Primary patency rate 61 48 43 42 31 
Secondary patency rate . . . . .  
Limb salvage rate . . . . .  
animal model. 17 Some clinical reports have also 
suggested that the addition o f  autologous tissue at 
the distal anastomosis might improve patency. Miller 
et a1.14 reported encouraging early results with the use 
of  vein cuffs, and more recently Taylor et al.ls used 
anastomotic vein patches at the tibioperoneal level in 
83 patients and reported patency rates at 1, 3, and 5 
years o f  74%, 58%, and 54%, respectively (Table 
VI). These patency rates are similar to ours at 1 year 
but are slightly better than our 3- and 5-year patency 
rates. However,  Taylor et al.ls used somewhat 
different indications for operation in their series, 
including claudication, which typically results in 
higher patency rates. In addition, their secondary 
patency rates were not materially better than their 
primary patency rates and were therefore not sub- 
stantially different from our secondary patency rates. 
L imb salvage results were not reported by this group. 
Moreover, in a recent series by Fichellc et al.,2s no 
benefit co,Md be demonstrated with the use of  vein 
patch angioplasty compared with standard anasto- 
moses. Thus, although the use of  adjunctive cuffs or 
patches may confer some advantage, to date this has 
not been proven. 
When lower extremity vein is unavailable, the 
second choice at many centers is arm vein if it is o f  
adequate quality and length. 29"a4 However,  when 
multiple segments o f  vein were required, patency 
rates were observed to be worse. 29,34 When single- 
segment cephalic vein grafts were used for infrapop- 
liteal bypasses in selected patients, the patency rates 
reported were 72% and 68% at 3 and 5 years, 
respectively, with limb salvage rates o f  85% at 5 years 
(Table VII). 29"33 However,  in a recent study by 
Londrey et al.29 of  257 grafts constructed from arm 
veins, with most o f  the bypasses (90%) to an 
infrapopliteal artery, the overall secondary patency 
rates (52% and 43% at 3 and 5 years, respectively) 
were not significantly different from those obtained 
in our series using PTFE alone. L imb salvage rates in 
this study were 74% and 69% at 3 and 5 years, 
respectively (Table Vii).  29 In their study composite 
grafts, which were defined as multiple segments o f  
arm vein, had significantly lower patency rates at 3 
and 5 years (39% and 29%, respectively). Unfortu- 
nately, when a bypass to the tibial level is necessary, 
multiple segments o f  arm vein are often required. 
Our  results are almost as good as those reported by 
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Table VI. Patency and limb salvage rates for PTFE bypasses performed with adjunctive vein cuffs 
to the infrapopliteal level 
1 Year 2 Years 3 Years 5 Years 
Author No. of patients (%) (%) (%) (%) 
Taylor et aL, 1992 is 256 
Pr imary patency rate 74 64 58 54 
Secondary patency rate . . . .  
L imb salvage rate . . . .  
Fichelle et al., 199525 65 
Pr imary patency rate 63 54 45 45 
Secondary patency rate . . . .  
L imb salvage rate . . . .  
Morr is et al., 199327 92 
Pr imary patency rate 51 40 29 - 
Secondary patency rate . . . .  
L imb salvage rate 74 - 64 - 
Wolfe and Tyrrell, 199128 55 
Pr imary patency rate - - 52 - 
Secondary patency rate . . . .  
L imb salvage rate . . . .  
Table VII.  Patency and limb salvage rates for arm vein bypasses to the infrapopliteal level 
I Year 2 Years 3 Years 5 Years 
Author No. of patients (%) (%) (%) (%) 
Sesto et al., 19923o 35 
Pr imary patency rate 49 49 40 - 
Secondary patency rate 68 58 44 - 
L imb salvage rate 82 82 82 - 
Harward  et al., 199232 43 
Pr imary patency rate 67 58 49 - 
Secondary patency rate 74 64 64 - 
L imb salvage rate 74 63 63 - 
Chalmers et al., 199331 42 
Pr imary patency rate 51 46 - - 
Secondary patency rate 85 85 - - 
L imb salvage rate . . . .  
Londrey et al., i99429 
Single segment 169 
Pr imary patency rate . . . .  
Secondary patency rate 78 - 60 52 
Mul t isegment  88 
Pr imary patency rate . . . .  
Secondary patency rate 56 53 39 29 
Overall  l imb salvage rate 85 80 74 69 
Londrey et al.29 for single segment upper extremity 
vein bypasses and are somewhat better than those in 
which multiple segments of arm vein are used for a 
crural bypass. In our experience, arm vein has often 
been unsuitable for long tibial and pedal bypasses 
because of its small size, the presence of sclerotic 
segments, or inadequate length, which mandated 
that multiple segments be anastomoscd to provide a 
graft of adequate length. However, the precise 
number of venous anastomoses that can be per- 
fbrmed before an "all autologous policy" should be 
abandoned has yet to be determined. 
In conclusion, we believe that the results in this 
report continue to support the use of PTFE for 
bypasses to the infrapopliteal level as a valuable part 
of an aggressive approach to limb salvage when 
adequate autologous vein is unavailable in a patient 
with advanced limb-threatening ischemia. Wc believe 
that the use of PTFE is a better option than use of 
poor quality vein and may even be superior to 
JOURNAL OF VASCULAR SURGERY 
354 Parsons et al. February 1996 
mul t ip le  arm vein segments.  The  benefits o f  vein 
cuffs, patches,  or  AVFs  have not  as yet  been proven,  
and large, randomized ,  prospect ive trials wi l l  be 
necessary to conf i rm their  value in this sett ing. 
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DISCUSSION 
Dr. William J. Quifiones-Baldrich (Los Angeles, 
Calif.). It has often been said that primary patency 
underscores the performance of a conduit in a particular 
location, whereas econdary patency denotes the determi- 
nation of the surgeons caring for the patient o accomplish 
limb salvage. This particular study is remarkable, mainly 
because of the limb salvage rates of 71% at 3 years and 66% 
at 5 years with the use of PTFE bypasses to tibial vessels in 
the management of limb-threatening ischemia. 
On the other hand, their primary patency rate is not 
different from those previously reported by other investi- 
gators. These rates continue to be dismal- in the order of 
30% to 40% at 3 years. Other investigators, such as Taylor 
who used a Taylor patch, have reported somewhat im- 
proved resuks. Although the authors claim that their results 
are not much different from those reported by Taylor, ~s in 
reality Taylor reported a3 year patency rate of 58%, which 
at first glance appears to be better than the rate of 39% 
reported in this series. This brings up the difficulties of 
comparing 'retrospective studies wherein many factors 
influence the results. 
Throughout the study the authors make comparisons 
between their secondary patency rate and the primary 
patency rates reported by others. Again, this lends itself to 
significant errors and therefore is to be avoided. I believe it 
is inappropriate o conclude from this study that a PTFE 
bypass to a tibial artery performs equally well with or 
without adjunctive surgical procedures. I agree with the 
authors when they state that a randomized trial would be 
necessary to answer this important question. 
The authors state that 82% of their patients had 
previous vascular econstructions that had failed and then 
required reintervention. Yet they report that a significant 
number of their patients whose PTFE tibial grafts failed did 
not require additional revascularization. Why such a 
discrepancy? In our experience the more distal the femo- 
rotibial reconstruction, the closer the patency rate and the 
limb salvage rate become. As you go from the femoral 
artery for revascularization, the limb is more and more 
dependent on patency of the bypass for its survival. This 
may be different for tibial bypasses that originate in the 
popliteal artery where failure of the reconstruction may be 
tolerated by the extremity as a result of existing collateral 
flow. Do you have any experience with short PTFE 
bypasses to distal tibial arteries? What would be your 
recommendation fora patient with adequate inflow to the 
popliteal artery who requires a prosthetic tibial bypass? 
One of the factors that most likely has improved the 
primary patency rate in this particular series is the routine 
use of long-term anticoagulation i  patients undergoing 
tibial reconstruction with a prosthetic graft. There are two 
prospective studies that have shown improved long-term 
results in patients maintained with oral anticoagulation 
after infrainguinal reconstruction. This is a practice that we 
have adopted within our service where Conmadin is 
routinely recommended for patients who undergo reinter- 
vention after graft failure. In our experience a new bypass 
has better long-term results than bypasses that are revised 
with continued use of the original conduit. Have the 
authors een this difference? What criteria do they use to 
determine whether a new conduit should be placed or 
whether the old one can be revised? 
Clearly, the authors have an aggressive approach in 
managing the failed infrapopliteal PTFE graft. How has 
your logarithm for reintervention changed in the last 5 
years, specifically with thrombolytic agents and endovas- 
cular procedures? 
Finally, it is important to recognize that patency rates, 
when calculated by the life-table method, can appear 
improved when a high mortality rate is seen during 
follow-up. This is particularly the case in our patient 
population where it has been clearly shown that the severity 
of the lower extremity disease correlates with an increased 
mortality rate. Thus patients with the worse tibial disease, 
therefore with an anticipated lower patency rate, will have 
an increased mortality rate; consequently, a number of 
them will be eliminated from consideration because of 
death rather than graft failure. This is not to say that these 
patients do not benefit from the reconstruction. However, 
caution should be used in interpreting the results and more 
importantly in comparing these results with those from 
other series. 
In conclusion, I agree with the authors and their 
posture that a PTFE tibial bypass is preferable to an 
amputation in patients who lack autogenous vein for 
infrapopliteal reconstruction. The role of surgical adjuncts 
to improve the long-term results of these bypasses i yet to 
be determined as we continue our quest for the ideal 
substitute for the saphenous vein. 
Dr. Richard E. Parsons. While Dr. Taylor's primary 
patency was certainly better than ours, he reported that his 
primary and secondary patency rates were essentially the 
same. Therefore, I assume that his secondary patency rate 
was also around 58%, which is not much different from our 
secondary patency rate of 55%. 
I believe that many of the patients healed their foot 
lesions after their grafts failed, so that further intervention 
was not necessary. We tend to use the shortest possible 
bypass. Many of these bypasses do not originate in the 
common femoral artery. I believe that we should do a 
popliteal-tibial bypass for an infrapopliteal lesion with a 
patent superficial femoral artery. 
When not contraindicated, we routinely used Couma- 
din. However, Schweiger ~s used only aspirin in his series of 
almost 200 patients and obtained equivalent results. 
In regard to our algorithm after graft failure, more 
recently we have used lyric therapy as a first line. Based on 
what we find after lysis or thrombectomy, we then plan the 
revision. I realize that this is a very high-risk group of 
patients which can effect he life tables. But, unfortunately, 
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this is the patient populuation that we are working with. 
Dr. Enrico Ascer (Brooklyn, N.Y.). Eleven years ago, 
we presented data showing that high outflow resistance was 
a definite cause of failure in patients who had PTFE distal 
bypasses. We continued this work and found that some 
patients had such a high outflow resistance and such a low 
flow state in the graft that they would eventually throm- 
bose. That is when we began to study the concept hat 
perhaps AVFs could be used to treat these patients. Over 
the past 5 years we have treated aseries of patients in whom 
we used a modified version of the Dardik technique for 
performing an AVF. We used this technique in 68 patients 
and we had a 62% patency rate at 3 years and a limb salvage 
rate of more than 70%. Therefore, I believe that some 
patients would not require an AVF as an outlet o increase 
the flow through the distal graft. 
What is the cause of failure in the 66 grafts that you 
placed? Do you see any place for the AVF in high 
outflow-resistance systems? 
Dr. Parsons. I believe that there are two causes of 
failure of these grafts- intimal hyperplasia and progression 
of distal disease. Since the results in the few patients in our 
series who had arteriovenous fi tulas were worse than the 
results we have presented here, I do not see a role for AVFs. 
Dr. Michael F. Silane (New York, N.Y.). The 
comparison here seems to be between Gore-Tex with and 
without he Taylor patch. There is another major difference 
between the two studies-your patients were routinely 
given Coumadin, which has been shown in two studies to 
increase the patency rate. I believe that the Taylor study did 
not routinely use Coumadin. If their patients were also 
treated with what is now accepted as good treatment- 
Coumadin-they may even have had better esults in the 
Taylor group. 
Dr. Parsons. Yes, that might very well be the case. 
Unfortunately, no data are available to verify this and vein 
patches remain of unproven value. 
Mr. Jonathan J. Earnshaw (Gloucester, United King- 
dom). I want to tell you about a study that a group of 
surgeons in the United Kingdom (known as the Joint 
Vascular Research Group) have just finished wherein we 
did a randomized trial of patients in whom there was no 
saphenous vein available and they were randomized to 
either a plain PTFE graft or a PTFE graft with a Miller 
collar. 
Most of the patients had above-knee grafts and there 
was no significant difference between the patency rates 
regardless of whether it was with a cuff. However, below 
the knee we found both a clinically and a statistically 
signficant difference, with improved patency in those 
patients who had a Miller cuff. 
With respect o this study, I am unable to make a 
specific omment since there were not enough patients who 
had grafts to the tibial arteries. However, if the more distal 
you go the more significant avein cuff is likely to be, then 
we should expect hat a vein cuffwould be an advantage in
a tibial PTFE graft as well as in a below-knee one. 
Dr. Parsons. I do not think that this issue can be 
resolved without a randomized, prospective trial compar- 
ing PTFE alone with PTFE with the addition of a vein 
patch at the infrapopliteal level. In addition, the study we 
quoted by Fichelle 2s was randomized to vein cuff with 
PTFE or PTFE alone, and no difference was found 
between the two groups. 
